Isam Diab, MD
Rheumatology · Middleburg Hts, OHNPI 1063488765
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $23,573 of the $35,592 with a category attached, or 66.2%. It is spread thinly across 57 manufacturers, the largest accounting for just 19.2%. Reporting peaked in 2020 at $8,873 and has fallen 58.5% since, to $3,679 in 2025. Among rheumatology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,407 payments — averaging $25.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- Gilead$7K
- Lilly USA, LLC$4K
- AbbVie$2K
- Johnson & Johnson$2K
- UCB, Inc.$2K
- plus $11K from 51 others
Across 1,001 payments — averaging $15,276 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$8.1M
- Novartis$2.2M
- AbbVie$1.8M
- Sun Pharmaceutical Industries Inc.$854K
- Amgen$578K
- E.r. Squibb & Sons, L.L.C.$425K
- plus $1.3M from 16 others
What the payments were for
- Consulting fees$6,08817%
- Speaking & faculty fees$3,48010%
- Travel & lodging$1,8615%
- Food & beverage$23,57366%
- Education$5902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,592 in reported general payments places this provider in the 90th percentile of 255 rheumatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 12 | $530,456 |
| Humira(Cf) PenAdalimumab | 35 | $300,092 |
| Enbrel SureclickEtanercept | 19 | $193,838 |
| Orencia ClickjectAbatacept | 18 | $103,844 |
| Humira(Cf)Adalimumab | 14 | $92,551 |
| Xeljanz XrTofacitinib Citrate | 12 | $67,672 |
| OtezlaApremilast | 13 | $64,195 |
| Hydroxychloroquine Sulfate | 1,171 | $47,022 |
| Leflunomide | 517 | $31,327 |
| MethotrexateMethotrexate Sodium | 938 | $30,388 |
| Celecoxib | 462 | $23,966 |
| SavellaMilnacipran Hcl | 26 | $19,118 |
| Pregabalin | 318 | $11,496 |
| Pilocarpine Hcl | 114 | $10,934 |
| Prednisone | 1,119 | $10,849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $840 | $530,45612 claims |
| AbbVieHumira(Cf), Savella | $2,293 | $111,66940 claims |
| AmgenOtezla | $6,822 | $64,19513 claims |
| Hikma Pharmaceuticals USAMitigare | $53 | $4,71612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 rheumatology providers in Ohio.
Other rheumatology in Middleburg Hts
- Leonard CalabreseCleveland$1.9M
- Gregory DelorenzoCincinnati$1.3M
- Alexa MearaColumbus$426K
- Chad DealCleveland$375K
- David MandelMayfield Village$352K
- Muhammad KhanCleveland$262K
- Chacko AlappattMiamisburg$258K
- Adam BrownCleveland$247K
- Nikita HegdeStow$198K
- M Elaine HusniCleveland$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.